These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 34400331)

  • 1. Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.
    Baik AD; Calafati P; Zhang X; Aaron NA; Mehra A; Moller-Tank S; Miloscio L; Praggastis M; Giovannone N; Pan C; Tang Y; Bridges S; Mujica A; Barbounis P; Yanolatos J; Gale N; Li N; Kyratsous CA; Schoenherr CJ; Murphy AJ; Economides AN; Cygnar KD
    Mol Ther; 2021 Dec; 29(12):3512-3524. PubMed ID: 34400331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
    Meena NK; Raben N
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.
    Yi H; Sun T; Armstrong D; Borneman S; Yang C; Austin S; Kishnani PS; Sun B
    J Mol Med (Berl); 2017 May; 95(5):513-521. PubMed ID: 28154884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.
    Hsu J; Northrup L; Bhowmick T; Muro S
    Nanomedicine; 2012 Jul; 8(5):731-9. PubMed ID: 21906578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy for Pompe Disease: The Time is now.
    Colella P; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy.
    Prater SN; Patel TT; Buckley AF; Mandel H; Vlodavski E; Banugaria SG; Feeney EJ; Raben N; Kishnani PS
    Orphanet J Rare Dis; 2013 Jun; 8():90. PubMed ID: 23787031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes.
    Tiels P; Baranova E; Piens K; De Visscher C; Pynaert G; Nerinckx W; Stout J; Fudalej F; Hulpiau P; Tännler S; Geysens S; Van Hecke A; Valevska A; Vervecken W; Remaut H; Callewaert N
    Nat Biotechnol; 2012 Dec; 30(12):1225-31. PubMed ID: 23159880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
    Han SO; Li S; Bird A; Koeberl D
    Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
    Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
    Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease.
    Nilsson MI; MacNeil LG; Kitaoka Y; Suri R; Young SP; Kaczor JJ; Nates NJ; Ansari MU; Wong T; Ahktar M; Brandt L; Hettinga BP; Tarnopolsky MA
    Free Radic Biol Med; 2015 Oct; 87():98-112. PubMed ID: 26001726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of Potent Mannose 6-Phosphate Analogues for the Functionalization of Lysosomal Enzymes To Improve the Treatment of Pompe Disease.
    El Cheikh K; Basile I; Da Silva A; Bernon C; Cérutti P; Salgues F; Perez M; Maynadier M; Gary-Bobo M; Caillaud C; Cérutti M; Garcia M; Morère A
    Angew Chem Int Ed Engl; 2016 Nov; 55(47):14774-14777. PubMed ID: 27774736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Pompe disease in China: a report from the Pompe registry.
    Zhao Y; Wang Z; Lu J; Gu X; Huang Y; Qiu Z; Wei Y; Yan C
    Orphanet J Rare Dis; 2019 Apr; 14(1):78. PubMed ID: 30943998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pompe disease: from new views on pathophysiology to innovative therapeutic strategies.
    Parenti G; Andria G
    Curr Pharm Biotechnol; 2011 Jun; 12(6):902-15. PubMed ID: 21235442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Chaperone Therapy for Pompe Disease.
    Borie-Guichot M; Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.
    Koeberl DD; Li S; Dai J; Thurberg BL; Bali D; Kishnani PS
    Mol Genet Metab; 2012 Feb; 105(2):221-7. PubMed ID: 22154081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
    Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
    Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
    Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
    Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.